The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors.
Albiruni R A Razak
No relevant relationships to disclose
Morten Mau Soerensen
No relevant relationships to disclose
Amit Mahipal
No relevant relationships to disclose
Sharon Shacham
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Cindy Y. F. Yau
Research Funding - Ozmosis Research
Ulrik Niels Lassen
No relevant relationships to disclose
Dilara McCauley
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Jennifer Cooksey
No relevant relationships to disclose
David Shao Peng Tan
No relevant relationships to disclose
Jean-Richard Saint-Martin
Employment or Leadership Position - Karyopharm Therapeutics
Yossi Landesman
Employment or Leadership Position - Karyopharm Therapeutics
Gregory Pond
Research Funding - Ozmosis Research
Amit M. Oza
No relevant relationships to disclose
Michael Kauffman
Employment or Leadership Position - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics
Lillian L. Siu
Employment or Leadership Position - Agios (I); Bayer (Other); Boehringer Ingelheim; Bristol-Myers Squibb; Celgene (Other); EntreMed (I); GlaxoSmithKline (Other); Merck (Other); Novartis (Other); Pfizer Inc. (Other); Regeneron (Other)
Consultant or Advisory Role - Boehringer Ingelheim; Oncoethix
Stock Ownership - Agios (I); EntreMed (I); Rigel Pharmaceuticals Inc. (I)
Mansoor Raza Mirza
Employment or Leadership Position - Karyopharm Therapeutics
Consultant or Advisory Role - Karyopharm Therapeutics
Stock Ownership - Karyopharm Therapeutics